| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 158, Issue 12 5619-5626, Copyright © 1997 by American Association of Immunologists
ARTICLES |
T Fujimoto, RB Duda, A Szilvasi, X Chen, M Mai and MA O'Donnell
Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Streptococcal preparation OK-432 is a bacterial immunopotentiator extensively used in Japan for adjuvant cancer therapy. Using a C57BL/6 mouse model, OK-432 was found to induce multiple cytokines including the Th1 polarizing cytokine IL-12. Expression of IL-12 protein by murine splenocytes was restricted to macrophages and B cells and led to high levels of IFN-gamma production from both CD4+ and CD8+ T cells. Of the Th2 cytokines IL-4 and IL-10, only IL-10 protein was detected and originated primarily from the adherent cell population. Its expression was delayed relative to IL-12. A similar pattern of cytokine induction was observed from human PBMCs. OK-432-driven IFN-gamma production was inhibited by anti-IL-12 Ab, anti-IL-2 Ab, anti-TNF-alpha Ab, and anti- IL-2R alpha Ab, suggesting that IFN-gamma production from Th1 cells is induced by the cooperation action of these cytokines through the IL-2R alpha pathway. When compared with another widely used immunopotentiator bacillus Calmette-Guerin (BCG), OK-432 was a stronger IL-12 and IFN- gamma inducer. Furthermore, the mechanism of IFN-gamma induction by OK- 432 differed from BCG in that coincident granulocyte-macrophage CSF and IL-1 expression played little to no role. These results suggest that OK- 432 is a potent multicytokine inducer, specifically a strong inducer of IL-12, and that OK-432 may exert its antitumor effect by promoting a Th1-dominant state.
This article has been cited by other articles:
|
|
 |
|
  S. Koido, E. Hara, S. Homma, M. Mitsunaga, A. Takahara, E. Nagasaki, H. Kawahara, M. Watanabe, Y. Toyama, S. Yanagisawa, et al. Synergistic Induction of Antigen-Specific CTL by Fusions of TLR-Stimulated Dendritic Cells and Heat-Stressed Tumor Cells J. Immunol., October 1, 2007; 179(7): 4874 - 4883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Koido, E. Hara, S. Homma, A. Torii, M. Mitsunaga, S. Yanagisawa, Y. Toyama, H. Kawahara, M. Watanabe, S. Yoshida, et al. Streptococcal Preparation OK-432 Promotes Fusion Efficiency and Enhances Induction of Antigen-Specific CTL by Fusions of Dendritic Cells and Colorectal Cancer Cells J. Immunol., January 1, 2007; 178(1): 613 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Okamoto, S. Furuichi, Y. Nishioka, T. Oshikawa, T. Tano, S. U. Ahmed, K. Takeda, S. Akira, Y. Ryoma, Y. Moriya, et al. Expression of Toll-Like Receptor 4 on Dendritic Cells Is Significant for Anticancer Effect of Dendritic Cell-Based Immunotherapy in Combination with an Active Component of OK-432, a Streptococcal Preparation Cancer Res., August 1, 2004; 64(15): 5461 - 5470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nakahara, T. Tsunoda, T. Baba, S. Asabe, and H. Tahara Dendritic Cells Stimulated with a Bacterial Product, OK-432, Efficiently Induce Cytotoxic T Lymphocytes Specific to Tumor Rejection Peptide Cancer Res., July 15, 2003; 63(14): 4112 - 4118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Okamoto, T. Oshikawa, T. Tano, G. Ohe, S. Furuichi, H. Nishikawa, S. U. Ahmed, S. Akashi, K. Miyake, O. Takeuchi, et al. Involvement of Toll-Like Receptor 4 Signaling in Interferon-{gamma} Production and Antitumor Effect by Streptococcal Agent OK-432 J Natl Cancer Inst, February 19, 2003; 95(4): 316 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Karlsson, C. Hessle, and A. Rudin Innate Immune Responses of Human Neonatal Cells to Bacteria from the Normal Gastrointestinal Flora Infect. Immun., December 1, 2002; 70(12): 6688 - 6696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mashino, N. Sadanaga, F. Tanaka, M. Ohta, H. Yamaguchi, and M. Mori Effective Strategy of Dendritic Cell-based Immunotherapy for Advanced Tumor-bearing Hosts: the Critical Role of Th1-dominant Immunity Mol. Cancer Ther., August 1, 2002; 1(10): 785 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nishimura, K. Iwakabe, M. Sekimoto, Y. Ohmi, T. Yahata, M. Nakui, T. Sato, S. Habu, H. Tashiro, M. Sato, et al. Distinct Role of Antigen-specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication In Vivo J. Exp. Med., September 6, 1999; 190(5): 617 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kato, T. Manabe, Y. Tanaka, and H. Mochizuki Effect of an Orally Active Th1/Th2 Balance Modulator, M50367, on IgE Production, Eosinophilia, and Airway Hyperresponsiveness in Mice J. Immunol., June 15, 1999; 162(12): 7470 - 7479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Luo, X. Chen, T. M. Downs, W. C. DeWolf, and M. A. O'Donnell IFN-{alpha} 2B Enhances Th1 Cytokine Responses in Bladder Cancer Patients Receiving Mycobacterium bovis Bacillus Calmette-Guerin Immunotherapy J. Immunol., February 15, 1999; 162(4): 2399 - 2405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Miettinen, S. Matikainen, J. Vuopio-Varkila, J. Pirhonen, K. Varkila, M. Kurimoto, and I. Julkunen Lactobacilli and Streptococci Induce Interleukin-12 (IL-12), IL-18, and Gamma Interferon Production in Human Peripheral Blood Mononuclear Cells Infect. Immun., December 1, 1998; 66(12): 6058 - 6062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Sharma, M. Leite de Moraes, F. Zavala, C. Pontoux, and M. Papiernik Induction and Inhibition of CD40-CD40 Ligand Interactions: A New Strategy Underlying Host-Virus Relationships J. Immunol., November 15, 1998; 161(10): 5357 - 5365. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
